Tag Archives: Shire PLC

Ahead of Shire plc 3Q16 Results, Exane BNP Paribas Maintains Outperform Rating

UK’s premier pharmaceutical company Shire plc (NASDAQ: SHPG, LON:SHP) has been growing by leaps and bounds, especially over the past six months, thanks to its accelerated income and revenue growth. The latest news indicate further growth catalysts ahead for SHP,

John Paulson 4Q Picks: Shire PLC (ADR) (SHPG), Valeant Pharmaceuticals Intl Inc (VRX), Teva Pharmaceutical Industries Ltd (ADR) (VRX)

New York based hedge fund, Paulson & Co revised its portfolio after a harsh year with a 24.09% loss. The hedge fund, which currently has a portfolio value of $16.73B, made a few notable additions since the beginning of the

Shire Receives a Hold from RBC Capital

RBC Capital analyst Douglas Miehm reiterated a Hold rating on Shire (NASDAQ: SHPG) today and set a price target of $248. The company’s shares closed last Friday at $216.03. Currently, the analyst consensus on Shire is Moderate Buy and the

Jefferies Maintains a Buy Rating on Shire

In a report published on January 20, Peter Welford from Jefferies maintained a Buy rating on Shire (NASDAQ: SHPG), with a price target of $247. The company’s shares closed yesterday at $216.98. Currently, the analyst consensus on Shire is Moderate

RBC Capital Reiterates a Hold Rating on Shire

In a report published on January 12, Douglas Miehm from RBC Capital reiterated a Hold rating on Shire (NASDAQ: SHPG), with a price target of $238. The company’s shares closed yesterday at $206.59. Currently, the analyst consensus on Shire is

Shire PLC Initiated with a Buy at Goldman Sachs

In a report released today, Keyur Parekh from Goldman Sachs initiated coverage with a Buy rating on Shire PLC (NASDAQ: SHPG). The company’s shares opened today at $200. Currently, the analyst consensus on Shire PLC is Moderate Buy and the